VIENNA--(BUSINESS WIRE)-- Prior to the 20th Annual Meeting of the European Society of Clinical Microbiology and Infectious Diseases on April 10-13, 2010 in Vienna, Bruker Daltonics and KIESTRA Lab Automation announce an expanded partnership covering co-marketing and cross-selling of their respective technologies for microbiology routine laboratories, as well as a joint research and development program for interfacing their technologies.
In recent years, Bruker and KIESTRA Lab Automation have worked with a number of customers applying both technologies in their laboratories. Together with the Academical Medical Center (Amsterdam), the Jeroen Bosch Hospital (Den Bosch), Leiden University Medical Center (Leiden) and Streeklab Haarlem (Haarlem), both companies applied for the prestigious European Research Initiative EUREKA (www.eureka.be). Typically, EUREKA R&D is lead by industry and is focused on significant new customer requirements. In March 2010, the participating project partners ranked at third position of the EUREKA tender for their joint 24/7 Bacteriology Identification & Sensitivity System (BISS) project. In addition to integration of both technologies, a goal of the BISS project is to enable unattended 24/7 operation for bacterial identification.
Mr. Jetze Botma, Chief Executive Officer at KIESTRA Lab Automation, stated: “It is remarkable to see how relatively new players in the microbiology market have changed the competitive landscape in the last couple of years. The trends of consolidation of laboratories and of centralizing microbiology laboratory services will further increase the demand for professional automation solutions. In addition, an early identification by the MALDI Biotyper in many cases can already initiate a germ-specific therapy, which leads to a significant increase in laboratory and hospital efficacy. The effective combination of both technologies will help to ease the burden on the healthcare system.”
Dr. Wolfgang Pusch, Vice President for Clinical Research Solutions & IVD at Bruker Daltonics, added: “This strategic partnership with KIESTRA Lab Automation is an excellent match for Bruker. We are two leading suppliers offering innovative technologies for the microbiology market, in laboratory automation and in molecular microbial ID. Each of our technologies alone has been quite successful already, and in combination they could change the way microbiology is performed in many routine labs. KIESTRA´s technology brings the same level of automation into the microbiology lab that was introduced in clinical chemistry 15 years ago. Moreover, the MALDI Biotyper reduces the identification turnaround time for patient samples significantly. Both technologies integrated together will help microbiology laboratories to perform their important tasks faster and better, despite a predicted shortage in experienced laboratory staff.”
About the Bruker MALDI Biotyper
Bruker’s proprietary MALDI Biotyper solution enables molecular identification, taxonomical classification or dereplication of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry. Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product processing and quality control, as well as marine microbiology. Bruker’s robust MALDI Biotyper method requires minimal sample preparation efforts and offers low consumables cost per sample. The MALDI Biotyper is available in a research-use-only version, as well as in an IVD-CE version according to EU directive EC/98/79 in certain European countries. For more information, please visit www.maldibiotyper.com.
For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit www.bdal.com and www.bruker.com/.
About Kiestra’s MalditofA for Fully Automatic Colony Picking
Bruker’s MALDI-TOF technology is a true revolution within medical bacteriology. KIESTRA launches a full automatic colony picker, called MalditofA. The automatic transfer of a colony to the target plate by the MalditofA guarantees that possible manual mismatches are prevented. In order to enhance susceptibility testing, the MalditofA also automatically creates the suspension fluid at. e.g. 0.5 McFarland. The MalditofA makes sure laboratories can take advantage to reduce id-card usage while labor costs are reduced dramatically.
For more information about KIESTRA Lab Automation, please visit www.kiestra.nl.
CAUTIONARY STATEMENT OF BRUKER
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2009, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6243451&lang=en
CONTACT:
MALDI Biotyper Marketing, Bruker Daltonics
Karin Hoffmann, +49-421-2205-2041
[email protected]
or
KIESTRA Lab Automation
Anneke Dalstra, +31-512-510-710
[email protected]
KEYWORDS: Austria Europe
INDUSTRY KEYWORDS: Health Biotechnology Hospitals Medical Devices Pharmaceutical Research Science
MEDIA:
| Logo |
| Photo |
| Bruker's MALDI Biotyper with KIESTRA's MalditofA lab automation system. (Photo: Business Wire) |